Toubro S, Astrup A, Breum L, Quaade F
Research Department of Human Nutrition, Royal Veterinary and Agricultural University, Fredriksberg, Copenhagen, Denmark.
Int J Obes Relat Metab Disord. 1993 Dec;17 Suppl 3:S73-7; discussion S82.
This paper describes a 24-week open follow-up trial with reduced obese patients all receiving an ephedrine/caffeine combination (20 mg/200 mg) three times a day. The study was a continuation of a previous 24-week double-blind placebo-controlled study where the ephedrine/caffeine mixture had shown superior weight-reducing properties when compared with either ephedrine alone (20 mg) or caffeine alone (200 mg) three times a day. The medication was stopped between weeks 24-26 in order to evaluate withdrawal symptoms. The follow-up period was from weeks 26 to 50. Of 127 patients included, 99 completed the follow-up treatment, which resulted in an additional weight loss of 1.1 kg (P = 0.02). Adverse drug reactions were all minor and temporary. We conclude that the ephedrine/caffeine combination is safe and effective in long-term treatment in improving and maintaining weight loss. The side-effects are minor and transient and no clinically relevant withdrawal symptoms have been observed.
本文描述了一项针对肥胖症患者的为期24周的开放随访试验，所有患者每日三次服用麻黄碱/咖啡因组合制剂（20毫克/200毫克）。该研究是此前一项为期24周的双盲安慰剂对照研究的延续，在该研究中，与每日三次单独服用麻黄碱（20毫克）或单独服用咖啡因（200毫克）相比，麻黄碱/咖啡因混合物显示出更优的减肥效果。在第24至26周期间停药以评估戒断症状。随访期为第26周至50周。纳入的127例患者中，99例完成了随访治疗，这导致体重额外减轻了1.1千克（P = 0.02）。药物不良反应均较轻微且为暂时性。我们得出结论，麻黄碱/咖啡因组合制剂在长期治疗中对于改善和维持体重减轻是安全有效的。副作用轻微且短暂，未观察到具有临床意义的戒断症状。
